Characteristic | ||
---|---|---|
Baseline characteristics | ||
Female, n (%) | 46 (87) | |
Ethnicities, n (%) | ||
White | 20 (38) | |
Asian | 16 (30) | |
Black | 10 (19) | |
Other | 7 (13) | |
Age at diagnosis of SLE, yrs, median (IQR) | 15.0 (12.5–16.3) | |
Age at diagnosis of psySLE, yrs, median (IQR) | 16.1 (14.1–16.8) | |
Systems involved at diagnosis of SLE*, n (%) | ||
Skin | 45 (90) | |
Mucosal | 10 (20) | |
Musculoskeletal | 23 (46) | |
Serositis | 6 (12) | |
Hematological | 38 (76) | |
Renal | 12 (24) | |
Clinical features at time of diagnosis of psySLE | Concurrent (≤ 6 weeks) Diagnosis of SLE and psySLE, n = 27 | Later Diagnosis (> 6 weeks) of psySLE, n = 26 |
Age at diagnosis psySLE, yrs, median (IQR) | 16.3 (14.5–16.8) | 15.2 (13.5–17.0) |
Concomitant renal involvement, n (%) | 6 (22) | 3 (12)** |
SLEDAI without psySLE, median (IQR) | 8.0 (4.0–14.0) | 5.5 (2.0–8.0) |
ECLAM without psySLE, median (IQR) | 5.0 (3.0–7.0) | 3.0 (2.0–5.5) |
Incident dose of prednisone at diagnosis of psySLE, mg/kg, median (IQR)† | 0 | 0.15 (0.00–0.39) |
Autoantibodies present at diagnosis of psySLE††, n (%) | ||
ANA | 24 (92) | 24 (100) |
Anti-dsDNA | 8 (31) | 7 (32) |
Anti-Ro | 8 (36) | 6 (46) |
Anti-La | 3 (14) | 3 (23) |
Anticardiolipin | 7 (33) | 6 (40) |
Anti-RNP | 7 (29) | 5 (31) |
Anti-Sm | 7 (30) | 6 (38) |
↵* Based on 50 patients; 3 had insufficient details of their clinical SLE features at diagnosis to be included.
↵** One patient in this group did not have sufficient clinical details for inclusion.
↵† Based on 49 patients.
↵†† ANA results available for 50 patients, anti-dsDNA results for 48 patients, anti-Ro results for 35 patients, anti-La results for 34 patients, ACL results for 36 patients, anti-RNP results for 40 patients, and anti-Sm results for 39 patients. IQR: interquartile range; SLEDAI: SLE Disease Activity Index; ECLAM: European Consensus for Lupus Activity Measure; ANA: antinuclear antibody.